

**For the use of a Registered Medical Practitioner or a Hospital or a Laboratory
only**

DEBRIFREE

1. Generic Name

Papain - Urea Ointment

2. Qualitative and quantitative composition

Each gm of Ointment contains:

Papain I.P. ≥ 521700 Units

Urea I.P. 100 mg

Preservative:

Methyl Paraben I.P. 2 mg

Propyl Paraben I.P. 0.2 mg

Excipients q.s.

Excipients used are Potassium Phosphate Monobasic, Glycerol, Emulsified wax, Isopropyl Palmitate, Methyl Paraben, and Propyl Paraben.

3. Dosage form and strength

Dosage form: Ointment

Strength: Papain I.P. ≥ 521700 Units, Urea I.P. 100 mg

4. Clinical particulars

4.1 Therapeutic indication

DEBRIFREE is indicated for debridement of necrotic tissue.

4.2 Posology and method of administration

A tube of DEBRIFREE should be used on a single patient only.

Care should be taken during use to avoid microbial contamination and spoilage. Hands should be washed thoroughly before applying DEBRIFREE.

Tip of the tube should not come in contact with the wound or any other surface.

The ointment should be applied directly to the lesion and the covered with appropriate dressing. Daily or twice daily changes of dressings preferred.

4.3 Contraindications

DEBRIFREE is contraindicated in patients with known hypersensitivity to the active substance or to any of the excipient of this product.

4.4 Special warnings and precautions for use

Avoid contact with the eyes and mucous membranes. If irritation occurs, discontinue use temporarily and consult a physician.

Apply with caution only to damaged or inflamed skin or to the face.

The product should be used under medical supervision in babies.

4.5 Drugs interactions

Hydrogen peroxide solution may inactivate the papain. Precautions to avoid hydrogen peroxide during the wound cleansing process.

Urea may enhance the efficacy of topical formulations of 5-fluorouracil and dithranol, and increase the release and the permeation into the skin of active ingredients from other topical products such as corticosteroids.

The salts of heavy metals such as lead, silver, and mercury may inactivate papain. Therefore, contact with topical medications containing these metals should be avoided on the wound treated with Papain-Urea.

4.6 Fertility, pregnancy and lactation

There are no clinical data available concerning use in pregnancy.

There are no adequate experimental animal studies available concerning the effects on pregnancy, embryonic development, foetal development and/or post-natal development.

Caution must be exercised for use during pregnancy. However, indications of risks associated with topical applications of medicine during pregnancy and while breast-feeding are not known.

In breast-feeding women, the caution should be taken.

4.7 Effects on ability to drive and use machines

Not Available

4.8 Undesirable effects

DEBRIFREE is generally a well-tolerated and non-irritating formulation. A transient burning sensation may be experienced by a small percentage of patients upon apply DEBRIFREE. Occasionally, the profuse exudates from enzymatic digestion may irritate the skin. In such cases, more frequent dressing changes will alleviate discomfort until exudates decreases. There were no product related adverse events observed during study period in efficacy evaluable population during reported clinical trial.

4.9 Overdose

Intoxication after the use of DEBRIFREE is not known and is not to be expected due to the composition of the preparation. Skin irritation caused by overdose subsides quickly when the preparation is discontinued.

5. Pharmacological properties

5.1 Mechanism of Action

Papain is proteolytic enzyme derived from fruit of Carica Papaya, is a potent digestant of non-viable protein matter, but is harmless to viable tissue. Papain is active over a wide range of pH (3-12). Papain is relatively ineffective when used alone as debriding agent and requires the presence of activators to stimulate its

digestive potency. In DEBRIFREE, papain is combined with urea, a denaturant of proteins to provide two supplemental chemical actions.

-To expose the sulfhydryl groups (activators of papains) by solvent action

-To denature the non-viable tissue in the lesions and render it more susceptible to enzymatic digestions. Pharmacological studies have shown that the combinations of papain and urea results in twice as much digestive activity as papain alone.

5.2 Pharmacodynamic properties

Urea

Pharmacotherapeutic group: Protectives and emollients.

ATC code: D02AE01

Urea is a recognised hydrating agent that has been widely used topically to treat dry or damaged skin.

Papain is proteolytic enzyme derived from fruit of *Carica Papaya*, is a potent digestant of non-viable protein matter, but is harmless to viable tissue. Papain is active over a wide range of pH (3-12). Papain is relatively ineffective when used alone as debriding agent and requires the presence of activators to stimulate its digestive potency. In DEBRIFREE, papain is combined with urea, a denaturant of proteins to provide two supplemental chemical actions.

-To expose the sulfhydryl groups (activators of papains) by solvent action

-To denature the non-viable tissue in the lesions and render it more susceptible to enzymatic digestions. Pharmacological studies have shown that the combinations of papain and urea results in twice as much digestive activity as papain alone.

5.3 Pharmacokinetic properties

Papain, is active over a pH range of 3 to 12. It is relatively ineffective when used alone as a debriding agent and requires the presence of activators to stimulate its digestive potency. The combination of papain and urea promotes two supplemental chemical actions. First, it exposes by solvent action, the activators of papain. Secondly, it denatures the nonviable protein matter in lesions; thereby rendering it more susceptible to enzymatic digestion. The combination of papain and urea has been shown in pharmacologic studies to result in twice as much digestive activity as papain alone


6. Nonclinical properties

Not available

7. Description

Papain is proteolytic enzyme or a mixture of enzymes obtained from the juice of the unripe fruit of *Carica papaya* Linn. Papain is white to light brown, amorphous or slightly granular powder; odour, characteristic.

Urea is the diamide of carbonic acid. Urea is a white, crystalline powder or transparent crystals; odourless or almost odourless, but may gradually develop a slight odour of ammonia upon long standing. The empirical formula is $\text{CH}_4\text{N}_2\text{O}$ and its molecular weight is 60.1 g/mol. The chemical structure of Urea is:



DEBRIFREE is off white colored viscous ointment. The excipients used are Potassium Phosphate Monobasic, Glycerol, Emulsified wax, Isopropyl Palmitate, Methyl Paraben, and Propyl Paraben

8. Pharmaceutical particulars

8.1 Incompatibilities

None stated

8.2 Shelf-life

Do not use later than date of expiry.

8.3 Packaging information

DEBRIFREE is pack in Laminated polyethylene tubes of 5g and 15g

8.4 Storage and handing instructions

Store in a dry place at a temperature not exceeding 30°C. Protect from light.

Keep out of reach of children

Keep the cap tightly closed after use.

9. Patient counselling information

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- **This medicine has been prescribed for you only.** Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

What is in this leaflet?

9.1. What DEBRIFREE is and what it is used for

9.2. What you need to know before you take DEBRIFREE

9.3. How to take DEBRIFREE

9.4. Possible side effects

9.5. How to store DEBRIFREE

9.6. Contents of the pack and other information

9.1 What DEBRIFREE is and what it is used for

DEBRIFREE ointment contains papain and urea in emulsified wax ointment base.

Papain is a protein-cleaving enzyme derived from papaya fruit (*Carica papaya*) and certain other plants. Topical drug products containing papain are used for the removal of dead or contaminated tissue in acute and chronic lesions. This product combines papain with other active ingredients, with urea which is intended to promote removal of unhealthy skin tissue, control local inflammation, reduce wound odors, and rehydrate skin.

DEBRIFREE ointment is indicated for debriment of necrotic tissues.

9.2 What you need to know before you take DEBRIFREE

If you are allergic to urea or any of the other ingredients of this.

An allergic reaction may include a rash or itching.

- On large areas of skin if you have renal impairment, talk to your doctor before using.

Warnings and precautions

Talk to your doctor or pharmacist before using DEBRIFREE.

- If irritation occurs, discontinue use temporarily and consult your doctor.
- Apply carefully only to damaged or inflamed skin or to the face
- Avoid getting DEBRIFREE in your eyes, mouth, nose or ears (mucous membranes). Upon accidental contact, rinse the affected area with clean water.
- DEBRIFREE should only be used under medical supervision in babies.

Other medicines and DEBRIFREE

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

DEBRIFREE might interfere with other medicines applied to the skin such as:

- Topical corticosteroids, which are a group of medicines used on the surface of the skin to reduce the redness and itchiness caused by certain skin problems.
- 5-fluorouracil, used to treat skin conditions such as horny growths of the skin (keratoses) and some skin cancers.
- Dithranol, which is used to treat psoriasis.

9.3 How to take DEBRIFREE

Always use this medicine exactly as described as your doctor or pharmacist have told you. Check with your doctor or pharmacist if you are not sure.

- DEBRIFREE is for external use only.
- First gently wash and dry the affected areas of your skin.
- Apply evenly to dry skin areas 2 to 3 times a day, or as advised by your doctor or pharmacist.
- Wipe away any excess cream with a tissue.
- Duration of treatment will depend on how quickly your condition improves.

If you use more DEBRIFREE than you should or accidentally swallow any of the cream

In the rare event that you use more DEBRIFREE or you accidentally swallow any of this product, seek medical advice.

If you forget to use DEBRIFREE

Do not worry if you forget to use your cream at the right time. When you remember, start using the product again as you did before.

If you have any further questions on the use of this medicine, ask your Doctor.

Pregnancy and breast-feeding

- If you are pregnant or breast-feeding, it may not be advisable to use this product, unless your doctor considers it essential.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

9.4 Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you experience redness, a burning sensation or itching of the skin after applying DEBRIFREE, wash the cream off and stop using it. Talk to your doctor or pharmacist.

9.5 How to store DEBRIFREE

Store in a dry place at a temperature not exceeding 30°C. Protect from light.

Keep the cap tightly closed after use.

Keep out of reach of children

9.6 Contents of the pack and other information

Each gm of Ointment contains:

Papain I.P. \geq 521700 Units and Urea I.P. 100 mg

Excipients used are Potassium Phosphate Monobasic, Glycerol, Emulsified wax, Isopropyl Palmitate, Methyl Paraben, and Propyl Paraben.

Preservative:

Methyl Paraben I.P 2 mg

Propyl Paraben I.P. 0.2 mg

10. Details of manufacturer

Virchow Biotech Private Limited

Survey No. 172 Part, Gagillapur, Dundigal- Gandimaisamma Mandal, Medchal-Malkajgiri District- 500 043, Telangana State, INDIA

11. Details of permission or licence number with date

30/RR/AP/2005/F/R issued on 11.09.2019

12. Date of revision

Not applicable

MARKETED BY



TORRENT PHARMACEUTICALS LTD.

IN/DEBRIFREE- \geq 521700 Units and 100 mg /Mar -20/01 /PI